Mycoplasma Testing in Biologic Manufacturing: Market Dynamics and Technical Essentials

Mycoplasma are among the smallest self-replicating organisms, with no cell wall. They can slip through sterilising filters, shrug off common antibiotics and sit undetected in a cell culture for weeks while quietly changing how the cells behave. For anyone making biologics, testing for them is not optional.

That makes mycoplasma testing a small but strategically important corner of the biologics testing market: mandatory, technically demanding and growing with cell and gene therapy. This guide explains why mycoplasma are so hard to catch, the rules and methods, where testing is required, who competes and what drives the economics.

The Market at a Glance

IMARC values the global mycoplasma testing market at about $1.13 billion in 2025 and forecasts $2.72 billion by 2034, a CAGR of roughly 10% (IMARC). Coherent Market Insights gives a similar picture: about $1.0 billion in 2024, rising to $1.9 billion by 2031 at 9.7% a year (Coherent Market Insights). Demand grows with biologics manufacturing, biosimilars and especially cell and gene therapy, because every mammalian cell culture process needs mycoplasma testing at several points.

Why Mycoplasma Are So Hard to Catch

Their small size (typically 0.2–0.3 µm) lets them pass through standard 0.22 µm sterilising filters. With no cell wall, they are unaffected by beta-lactam antibiotics such as penicillin. They grow slowly, have demanding nutritional needs (many require sterols), form tiny colonies and can persist in biofilms. Contaminated cultures may look normal while their metabolism, growth, protein expression and even glycosylation change.

Of the 200+ known species, a handful cause most cell culture contamination, including M. orale, M. hyorhinis, M. arginini, M. fermentans, M. hominis and Acholeplasma laidlawii. Test methods are validated against these.

The Regulatory Framework

Requirements are set out in the pharmacopoeias and agency guidance. USP <63> Mycoplasma Tests, European Pharmacopoeia 2.6.7 and the Japanese Pharmacopoeia describe the culture method, indicator cell culture and nucleic acid amplification techniques (NAT), with NAT accepted when properly validated against the reference methods. USP <1043> covers ancillary materials for cell, gene and tissue-engineered products, extending testing to raw materials and cell banks. FDA and EMA guidance for cell and gene therapies adds further expectations, because these products cannot be terminally sterilised.

For investors, the key point is that testing is non-discretionary and tied to manufacturing volume, so it continues through economic cycles. Inspectors also scrutinise method validation, testing frequency and how atypical results are investigated, which favours experienced labs.

Testing Methods

Method	How it works	Time to result	Market position
Culture (direct)	Samples grown on mycoplasma agar and in broth at 35–37°C	Up to 28 days	The long-standing reference method; still used as primary or confirmatory, but in decline
Indicator cell culture	Sample added to indicator cells, then stained (e.g. DNA fluorochrome) to reveal non-cultivable strains	About 1–2 weeks	Used alongside culture for compendial testing
NAT (PCR)	Amplifies mycoplasma-specific DNA, typically 16S rRNA genes, often with commercial validated kits	Hours to 1–2 days	Fastest-growing; essential for cell therapies
Emerging methods	Next-generation sequencing, digital PCR, biosensors and microfluidics	Varies	Promising but still working through validation and regulatory acceptance

“For a cell therapy with a two-week manufacturing window, a 28-day test simply doesn’t work.”

Rapid NAT testing typically costs around $500–1,500 per sample, depending on turnaround, volume and complexity, and expedited 24–48 hour results for cell therapy can cost two to three times standard pricing. Faster methods also raise lab throughput, but reliance on commercial kits narrows the technical gap between providers over time.

Where Testing Is Required

Cell bank testing links directly to cell line development (see our cell line development guide), and the extra testing burden of advanced therapies is covered in our guide to cell therapy types.

What Contamination Costs

The economics of this market rest on a simple asymmetry: a test costs hundreds or thousands of dollars, while a contamination event can cost millions in lost batches, investigations, cleaning and delays. Once established, mycoplasma are hard to eradicate because they persist in biofilms and porous materials, so remediation often needs specialist investigation, enhanced environmental monitoring and repeated testing.

This shapes buying behaviour. Customers favour labs with long regulatory track records, pay more for speed because early detection limits losses, and sometimes use more than one method or provider for added assurance. Contamination events also create follow-on work: investigation support, intensive testing and enhanced monitoring programs.

Competitive Landscape

• Large testing groups such as Charles River Laboratories, Eurofins, SGS and others offer mycoplasma testing within broad biologics safety panels, with global networks and strong regulatory track records.
• Specialists focus on cell and gene therapy, viral vectors or fast turnaround, and compete on expertise and service.
• Kit and platform suppliers such as Thermo Fisher (MycoSEQ), Lonza (MycoAlert, a rapid enzyme-based screen) and Merck KGaA sell systems and reagents to in-house labs and contract testers, earning recurring consumables revenue. Validated methods are costly to replace, which creates switching costs.

The market is gradually consolidating. Large testing groups acquire specialists for capabilities and geography, and private equity backs platforms that bundle mycoplasma testing with sterility, endotoxin, viral safety and other biologics tests.

Economics

Established labs can earn gross margins of roughly 45–60%, with specialised and expedited work higher. A basic mycoplasma lab (BSL-2 space, incubation and PCR equipment) might cost $0.5–2 million, but scaling also needs trained staff, method validation and regulatory qualification, typically 12–24 months for new capacity.

Margin pressure comes from kit-based commoditisation, lower-cost regional competitors and consolidating pharma buyers. The best defence is to move from “a test result” to “a contamination-control partner”: sample-specific validation, rapid release testing, investigation support and environmental monitoring.

Risks to Underwrite

• Commoditisation. Standardised kits narrow differentiation and invite price competition.
• Method shifts. New technologies (NGS, digital PCR) or regulatory changes could favour labs that invest early and strand older capacity.
• Quality failures. A false negative or an inspection finding at a lab can quickly damage its reputation with customers.
• End-market dependence. Cell and gene therapy growth has been uneven, and funding cycles affect development-stage volumes.
• Capacity constraints. Slow scaling can mean turning away work during demand spikes.

What This Means for Investors

Mycoplasma testing offers mandatory, recurring demand, strong pricing power where speed and reliability matter, and exposure to the fastest-growing part of biologics. The most valuable providers combine rapid validated methods with deep regulatory credibility and broader contamination-control services. When evaluating a target, we’d focus on:

• What share of volume comes from cell and gene therapy versus traditional biologics and vaccines?
• Which methods are validated, for which sample types, and how fast are typical turnarounds?
• What is the lab’s regulatory track record, including audits, inspections and any invalidated results?
• How much revenue comes from bundled biologics safety testing and investigation work versus single tests?
• How exposed is pricing to kit commoditisation and lower-cost competitors?
• Is there capacity, and a hiring plan, to support growth?

Terraforme Biosciences supports investors with technical and commercial due diligence on life sciences service businesses. Learn more about our M&A support.